MERIDIAN BIOSCIENCE INC
Healthcare · In Vitro & In Vivo Diagnostic Substances · OH · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $333.0M | $317.9M | $253.7M | $201.0M | $213.6M | $200.8M |
| Operating income | $54.4M | $93.0M | $61.3M | $32.7M | $31.6M | $37.4M |
| Net income | $42.5M | $71.4M | $46.2M | $24.4M | $23.8M | $21.6M |
| Total assets | $463.1M | $449.7M | $405.3M | $325.5M | $251.4M | $249.8M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $368.1M | $328.3M | $247.6M | $191.0M | $175.4M | $169.6M |
| EPS (diluted) | $0.96 | $1.62 | $1.07 | $0.57 | $0.56 | $0.51 |
| Shares out. | 43.8M | 43.4M | 43.1M | 42.7M | 42.4M | 42.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- 16.3%
- Net margin
- 12.7%
- Return on equity
- 11.5%
- Return on assets
- 9.2%
- Return on capital (ROCE)
- 13.4%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $8.40
- Revenue growth (YoY)
- 4.8%
- Net income growth (YoY)
- −40.5%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Accruals / assets
- −8.6%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- IDKIT:HPDec 17, 2002
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventFeb 1, 2023
- Entered a material agreement · Other material eventDec 12, 2022
- Results of operations · Regulation FD disclosureNov 22, 2022
- Shareholder vote · Other material eventOct 11, 2022
- Other material eventSep 30, 2022
- Results of operations · Regulation FD disclosureAug 5, 2022
- Other material eventJul 29, 2022
- Entered a material agreement · Completed an acquisition or disposition · Director / officer changeJul 7, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.